The Myocardial Infarction drugs in development market research report provides comprehensive information on the therapeutics under development for Myocardial Infarction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Myocardial Infarction. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Myocardial Infarction and features dormant and discontinued products.
GlobalData tracks 144 drugs in development for Myocardial Infarction by 134 companies/universities/institutes. The top development phase for Myocardial Infarction is preclinical with 73 drugs in that stage. The Myocardial Infarction pipeline has 119 drugs in development by companies and 25 by universities/ institutes. Some of the companies in the Myocardial Infarction pipeline products market are: AstraZeneca, Boehringer Ingelheim International and Heqet Therapeutics.
The key targets in the Myocardial Infarction pipeline products market include P2Y Purinoceptor 12 (ADP Glucose Receptor or P2Y12 Platelet ADP Receptor or SP1999 or P2T(AC) or P2Y(AC) or P2Y(cyc) or P2Y12 or P2RY12), Plasminogen (Plasmin or PLG or EC 3.4.21.7), and Prostaglandin G/H Synthase 1 (Cyclooxygenase 1 or COX1 or Prostaglandin Endoperoxide Synthase 1 or Prostaglandin H2 Synthase 1 or PTGS1 or EC 1.14.99.1).
The key mechanisms of action in the Myocardial Infarction pipeline product include Plasminogen (Plasmin or PLG or EC 3.4.21.7) Activator with three drugs in Phase I. The Myocardial Infarction pipeline products include 20 routes of administration with the top ROA being Intravenous and 18 key molecule types in the Myocardial Infarction pipeline products market including Small Molecule, and Cell Therapy.
Myocardial Infarction overview
Myocardial infarction is the irreversible necrosis of heart muscle secondary to prolonged ischemia. Symptoms include pain, fullness, and/or squeezing sensation of the chest; jaw pain, toothache, or headache; shortness of breath; nausea, vomiting, and/or general epigastric discomfort; sweating, heartburn and/or indigestion; arm pain; upper back pain; and general malaise (vague feeling of illness).
For a complete picture of Myocardial Infarction’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
